Key Insights

Highlights

Treatment Research

2 treatments under study, led by Tocilizumabtocilizumab Biosimilar

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05846789Phase 2Recruiting

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Showing all 1 trials

Research Network

Common Treatments

  • Tocilizumabtocilizumab Biosimilar1
  • Soc Chemotherapy1

Active Sponsors

  • Kathy Miller1
  • Breast Cancer Research Foundation1
  • Susan G. Komen Breast Cancer Foundation1
  • Genentech, Inc.1

Top Investigators

Related Conditions

  • Metastatic Breast Cancer1
  • Triple Negative Breast Cancer1
  • Er Positive Her2 Negative Breast Cancer1

Activity Timeline